Coronavirus
The company, Biotech company Moderna Inc. dosed 45 patients between the ages of 18 and 55 with 25, 100 or 250 micrograms of its experimental drug.
After receiving a second booster shot, those at the 25 and 100 dosage levels were found with antibody levels that were equal to or exceeded those found in patients who recovered from the COVID-19, the company said in a press release.
Moderna CEO Stephane Bancel told Bloomberg that the results “couldn’t have been better.”
“This is a very good sign that we make an antibody that can stop the virus from replicating,” he said.
The experimental vaccine, mRNA-1273, was found to be “generally safe and well tolerated” among patients, the company said. Further testing will begin in July.
Moderna stock soared 26 percent in pre-market trading Monday.
You may be interested
NFF Settled For Finidi Due To Financial Constraint –Ikpeba
Webby - April 29, 2024Former Nigerian international, Victor Ikpeba has finally disclosed why the Nigeria Football Federation (NFF) settled for Finidi George as the…
Serie A: Lookman On Target As Atalanta Overcome Empoli
Webby - April 28, 2024Super Eagles star, Ademola Lookman was on target as Atalanta defeated Empoli 2-0 in Sunday’s Serie A game.The Nigerian international…
Iwobi Surpasses Mikel’s Premier League Appearance Record
Webby - April 28, 2024Alex Iwobi has moved ahead of John Mikel Obi on the list of highest capped Nigerian players in the Premier…